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ABSTRACT

Purpose: Continuous flow (CF) left ventricular assist devices (LVAD) support
diminishes vascular pressure pulsatility. Despite its recent clinical success and
reliability, CF LVAD support has been associated with adverse events including
gastrointestinal bleeding, aortic valve insufficiency, and hemorrhagic strokes. To
overcome these limitations, we have developed flow/RPM modulation algorithms
to provide vascular pulsatility using a CF LVAD.

Methods: The effects of timing and synchronizing the CF LVAD flow/RPM
modulation to the native ventricle, modulation amplitude, and modulation widths
were studied on the native ventricle and vasculature using computer simulation,
mock loop, and animal model studies. A total of over 100 combinations of flow
modulation algorithms to modulate CF LVAD flow/RPM were tested for partial
and full LVAD support modes.

Results: Modulation of CF LVAD flow/RPM resulted in an increased arterial
pressure pulsatility of up to 50 mmHg during asynchronous modulation and 20
mmHg during synchronous modulation. Synchronous CF LVAD RPM modulation
allowed for a range of reduced left ventricular external work (LVEW) as
compared to un-modulated CF LVAD support conditions. Full support covi

pulsation (high RPM during systole, low RPM during diastole) created greater
pulse pressures as compared to counter pulsation (high RPM during diastole, low
RPM during systole). However, all full support modulation timings yielded higher
pulse pressure than normal full support CF LVAD flow at low ventricular
contractilities. Importantly, reduction in LVEW and increase in pulsatility may be
adjusted to user-defined values while maintaining the same average CF LVAD
flow rate.

Conclusions: These LVAD flow/RPM modulations may reduce the incidence of
adverse events associated with the CF LVAD therapy by increasing vascular
pulsatility and reducing vascular impedance. Further, these methods of CF LVAD
flow/RPM modulation may enable tailored unloading of the native ventricle to
provide rest and rehabilitation (maximal unloading to rest followed by gradual
reloading to wean), which may promote sustainable myocardial recovery.
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CHAPTER 1 - BACKGROUND

Epidemiology

Approximately 80 million Americans suffer from cardiovascular disease, which
has become the leading cause of death among both men and women in the
United States. Cardiovascular disease accounts for over 550,000 deaths per
year and led to a projected $450 billion in healthcare costs in 2009. Of these 80
million, six million will develop chronic heart failure (Figure 1) [1]. Furthermore,
one-year mortality rates for New York Heart Failure Association Class IV patients
exceed 60%.

Figure 1: Chronic heart failure rates in the United States continue to
increase, and are extrapolated to reach over 25 million Americans in
2015[1].
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Pathology

In congestive heart failure (CHF), the heart is unable to deliver the necessary
rate of sufficient blood, oxygen, and metabolites for the metabolic demands of
organs and tissues. CHF can occur both acutely and chronically depending on
the etiology of the disease. A patient can develop CHF abruptly in cases such as
sudden onset of fluid overload, valvular dysfunction or a severe myocardial
infarction. Chronically, heart failure can result due to persistent elevated work
requirements of the heart which may be secondary to valve disease,
hypertension, or ischemia among others. Further, reduced contractility can occur
due to weakening of the cardiomyocytes or stiffening of the myocardium during
CHF [2].

Physiology

During progression of CHF, mechanisms assist the heart and body to adapt to
meet metabolic needs. Myocardial contraction increases as diastolic volume
increases via increase in myosin-actin interaction, as described by the FrankStarling Mechanism. Ventricular remodeling occurs as an adaptation in early
2

stages of heart failure in efforts to maintain necessary cardiac output. However,
this can create an additive effect that eventually results in worsening heart failure.
Additionally, the autonomic nervous system can release norepinephrine to
increase the frequency of heart contractions. Similarly, the renin-angiotensinaldosterone pathway along with release of natriuretic peptide results in changes
in filling volumes and pressures. Early symptoms of left-sided failure are often
associated with pulmonary congestion and edema. Activation of the reninangiotensin-aldosterone system, caused by inadequate kidney perfusion, can
lead to an increase in pulmonary vessel pressure and subsequent onset of
hypoxia[3]. Furthermore, diminished arterial pressure pulsatility has been shown
to increase vascular impedance and reduce arterial relaxation [4, 5].

Treatments

The gold-standard treatment for these patients, cardiac transplantation, has a
50% 10-year survival rate. While transplantation significantly improves the
patient’s quality of life[6], patients are required to take immunosuppressant
medications, weakening their immune system. The frequency of available donor
hearts limits the number of transplanted patients with less than 4,000 cardiac
transplant surgeries are performed in the U.S. annually. Furthermore, over the
3

past five years there has been no significant increase in transplant rates, which
suggests this therapy is not a practical long-term solution for the majority of CHF
patients (Figure 2). Thus, these untransplanted patients are viable candidates for
alternative therapy[7].

Figure 2: The number of heart transplant per year has not increased, and in
recent history has actually been decreasing in frequency [7].

Alternatives to cardiac transplantation include medicinal therapies, techniques,
and devices, which slow the deterioration of heart function and improve patients’
functional status. Rest and relaxation of the cardiac muscle has long been the
underlying theme of heart failure treatment. Originally, patients were sequestered
to bed rest and limited mobility. Thus, while waiting for transplant or other therapy,
the sick patients had a much-reduced quality of life from a combination of their
disease and their treatment, including being bed-ridden and a forced reduction in
their daily activities. Currently, medicinal therapies seek to reduce the afterload
and disrupt the β-adrenergic receptor blockade. Medicinal therapies include the

4

administration of diuretics, angiotensin-converting enzyme (ACE) inhibitors,
angiotensin II receptor blockers, beta-blockers, and others[8]. Yet, perhaps the
most rapidly growing therapy in cardiovascular disease is mechanical circulatory
support.

Development of mechanical circulatory support

In 1964, The National Heart Institute established the Artificial Heart Program. The
following year, the National Institute of Health requested $40 million for the
upstart of the program. Dr. Denton Cooley implanted the first American artificial
heart in 1969 as a bridge to transplant. The device supported the patient for 64
hours till a heart could be found, however the patient survived little more than 30
hours post-transplant. Later that year, an NHI sponsored group on Cardiac
Replacement concluded that left ventricular assist devices (LVAD) would be a
promising area of research due to the current engineering short comings in
developing a completely artificial heart (i.e. TETS system, biocompatibility issues,
durability)[9].

In the three decades following the suggestion to explore the development of
LVAD, solutions were found to a number of underlying issues that plagued the
5

original artificial heart programs. Specifically, engineers had sufficiently answered
the issues of material biocompatibility and the life threatening driveline infections
to make LVAD a legitimate therapy for end-stage heart failure patients. The use
of textured titanium surface, titanium alloys, polymers and other biocompatible
materials allowed for chronic device implantation without the risk of a clinically
significant reaction[10]. Further, experience with cannula designs and drivelines
resulted in improvements of the percutaneous lines that exit the body and
resulted in reducing the infection risk[11].

The majority of devices developed during these three decades were categorized
by their pulsatile flow that mimicked the native heart. The devices used
membranes that were actuated, using a fill and eject cycle, similar to the native
ventricle. The first generation of implantable pulsatile flow LVADs (Thoratec IVAD
and HeartMate XVE, Worldheart Novacor) weighed up to 1kg and took up to one
half liter (volume) of space inside the implanted patient abdominal cavity. The
size restriction excluded smaller males, and most females as candidates for
therapy [12]. These pulsatile flow mechanical circulatory support devices were
effective in providing long-term (> 6 months) support.

However, the durability of the pulsatile pumps was sub-optimal (~18 months).
The pulsatile device has a predictably high incidence of mechanical failure in the
6

second year of support, with the most common failing mechanism being inflow
valve insufficiency [13]. The challenge of mechanical circulatory assist device
durability was addressed with the introduction of smaller, compact design,
second-generation blood pumps. Rotary pumps, which produce continuous, nonpulsatile flow, have reduced the number of moving parts to a single impeller/
rotor. The reduction in moving parts has resulted in clinical experience
demonstrating improved durability and lower power consumption [14].

Left ventricular assist device (LVAD) implantation has increased in popularity as
a therapeutic measure for bridging to transplantation in patients with end-stage
heart failure, and is gaining wider clinical acceptance as destination therapy in
patients ineligible for transplantation [14-16]. Further, there is hope that these
devices can be operated in such a way as to promote myocardial recovery.
During support they have been shown to be capable of partially reversing many
of the genetic, functional, and morphological hallmarks of the failing heart[17-23],
in addition to allowing device removal without transplantation in a small fraction
of patients[24, 25]. Recent evidence indicates that while there are differences in
the magnitude of unloading between pulsatile flow (PF) and continuous flow (CF)
pumps, both are capable of achieving normalization of some cellular damage
markers[26], and continuous flow pumps appear to be just as effective if not
better than pulsatile flow pumps in bridging patients to transplantation[27].
7

Furthermore, support in patients who do not meet transplant criteria, destination
therapy, has shown longer survival in continuous flow as compared to pulsatile
flow devices[14]. Given the apparent similarity in the survival benefit offered to
heart failure patients by these devices, CF LVAD has gained greater acceptance
as they have fewer moving parts, higher mechanical reliability[28], and are
considerably smaller, minimizing thrombogenic surface area and enabling
implantation in smaller adults as compare to their pulsatile counterparts.

Amidst the growing popularity of CF LVAD, however, there remain unanswered
questions regarding the long-term physiological effects of CF LVAD support. CF
LVAD significantly diminish vascular pressure pulsatility compared to PF LVAD
and anecdotal reports have indicated the development adverse events including
gastrointestinal bleeding, hemorrhagic strokes, increased vascular impedance,
and progression of aortic valve insufficiency in HF patients chronically supported
by CF LVAD [4, 29-31]. PF LVAD phasically unload the native ventricle, creating
variable loading of the native myocardium while maintaining end-organ perfusion,
which may affect weaning and promotion of myocardial recovery [32]. CF LVAD
continuously unload the native ventricle providing consistent ventricular loading.
However, this makes it difficult to modulate the myocardial load without altering
the LVAD flow and subsequently affecting the end-organ perfusion.

8

Gradual reloading of the heart while maintaining end-organ perfusion could be
achieved by modulation of blood pump motor speeds/flow. Modulation of blood
pump motor speeds/flow has been suggested as a potential mechanism to
artificially increase vascular pulsatility in both ventricular assist devices [33-39]
and total artificial hearts[40-43]. Flow modulation of ventricular assist devices is
affected by the timing of flow modulation to the native myocardial contraction.
Early LVAD modulation strategies focused on asynchronous modulation of LVAD
flow, as it was simpler to implement [33, 38]. Cox et al., Letsou et al., and Shi et
al. simulated sinusoidal synchronous LVAD flow modulation but did not vary the
timing of LVAD flow modulation [35, 36, 39]. Vandenberghe et al. varied the
timing of synchronous support but did not vary the LVAD flow modulation
amplitude or pulse width. Further, Vandenberghe et al. derived model
parameters from sheep which is different from human values [34] . The effects of
synchronizing and timing of the modulation of LVAD motor speeds/flow to the
native myocardium, modulation amplitude, and modulation width have only
recently been reported as a byproduct of this thesis work [44].

In this study, the effects of timing and synchronizing the LVAD motor speed and
flow modulation, modulation amplitude, and modulation widths on the native
ventricle and vasculature are investigated. Experiments were performed using a
computer simulation model, a mock circulation model, and acute animal studies.
9

CHAPTER 2 – COMPUTER SIMULATION

Introduction

Computer simulation is an important step in the design process for LVAD control
strategies and has been repeatedly shown valuable in the literature. Testing in
computer simulation is a financially efficient and time saving way to test multiple
iterations of various control designs. Several strategies of LVAD control have
been studied using computer simulation models including suction detection[4547], estimation and control of aortic pressure[48], exercise responsive control[49],
and preload dependent pump flow[50]. We hypothesized that modulation of
LVAD flow will increase arterial pressure pulsatility and alter left ventricular
pressures, volumes, and workloads. Further, the effect on the native ventricle will
be dependent on timing, amplitude, and pulse width of the LVAD flow modulation.
The objective of this computer simulation study was to investigate the effects of
timing and synchronizing LVAD flow modulation on the native ventricle and
vasculature with varying modulation amplitudes and widths.
10

Methods and Materials

Cardiovascular System Simulation

A previously reported computer simulation model of the human cardiovascular
system was modified to simulate heart failure using Matlab (Mathworks, MA).
This computer simulation model was validated and has been used in previous
studies to develop and test physiologic control strategies for mechanical
circulatory support devices [4, 51-53]. A more detailed description of the
simulation model is provided by Giridharan et. al[53].

Briefly, the computer model subdivides the human circulatory system into an
arbitrary number of lumped parameter blocks, each characterized by its own
resistance, compliance, pressure, and volume of blood. Two idealized elements,
resistance and storage, were used to characterize each block. The storage
element provides zero resistance to flow, whereas the resistive element has zero
volume. The model has 13 elements: four valves and nine blocks, including left
and right ventricles, pulmonary and systemic circulations, vena cava, aorta, and
coronary circulation (Figure 3). Ventricles were characterized by a time varying
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compliance. The remaining blocks were characterized by passive elements. The
coronary block consisted of time varying resistive and compliance elements.

Figure 3: Schematic of the lumped parameter human circulatory
system model.
LVAD Model

A model of a CF LVAD was integrated into previously published computer
simulation model. Simulations were conducted to predict acute hemodynamic
responses including coronary flows, ventricular pressure-volume loops, left
ventricular external work, arterial pressures, and vascular pulsatility parameters
(mean arterial pressure (MAP), energy equivalent pressure (EEP), surplus
hemodynamic energy (SHE)) for partial (mean LVAD flow = 2.5 ± 0.1 L/min) and
full LVAD support (mean LVAD flow = 5.0 ± 0.1 L/min) modes.
12

The LVAD flow modulation waveforms were constructed using a piecewisedefined function with no LVAD retrograde flows. CF LVAD retrograde flows
increase vascular pulsatility, but was not considered as they can increase
hemolysis and lead to higher myocardial loads and ventricular wall stresses. The
piecewise-defined function was divided into pulse and nadir phases (Figure 4a).
The pulse width was defined as the portion of the LVAD flow waveform where the
instantaneous flow equaled or exceeded the mean flow. The nadir phase was
defined as the portion of the LVAD flow waveform where the instantaneous flow
was less than or equaled the mean flow. Unification of the pulse and nadir
phases created one complete LVAD flow waveform. Pulse widths from 20%-80%
were simulated for each level of synchronous LVAD flow modulation. Pulse
widths of 40%, 50% and 60% were created with the same flow modulation
amplitudes and mean flows (Figure 4b). The pulse width conditions of 20%, 30%,
70%, and 80% required varying flow modulation amplitudes but maintained same
average flow rates. Both asynchronous LVAD flow modulation (20 beats/min, 40
beats/min, 60 beats/min) and synchronous LVAD flow modulation (80 beats/min)
were tested.
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Figure 4: (a) LVAD flow waveform with a 40% pulse width. (b) LVAD flow
waveforms with 40%, 50%, and 60% pulse width. (c) LVAD flow waveforms
with high, medium, and low flow modulation. (d) A 40% pulse width LVAD
flow waveform with a 40% and 60% time shift.

Different levels of LVAD flow modulation amplitudes were simulated for partial
and full LVAD support testing. Partial support LVAD flow modulations were
tested at low pulsatility, medium pulsatility, and high pulsatility. The amplitudes of
partial support LVAD flow modulations were 1 L/min, 2 L/min, and 4 L/min for low,
14

medium, and high pulsatility modes, respectively. The amplitudes of full support
LVAD flow modulations were 1 L/min, 4.5 L/min, and 9 L/min for low, medium,
and high pulsatility modes, respectively (Figure 4c). The effects of timing the
synchronous LVAD flow modulation to the native myocardial contraction were
tested by varying the time shift, which represents the timing of the LVAD flow
modulation in relation to the cardiac cycle (Figure 4d). Specifically, LVAD flow
modulation was initiated at 0% (co-pulsation mode - both native ventricular
contraction and LVAD flow modulation are in unison), 20%, 40% (counter
pulsation mode-LVAD flow modulation initiated during native ventricular diastole),
60%, and 80% of the native cardiac cycle, A total over 150 combinations of
varying pulse widths, beat frequencies, time shifts, and amplitudes of CF LVAD
flow were simulated.

All simulations were initiated with limit cycle (steady state) values of a failing
heart. At time t=0, the simulated device was turned on with a flow modulation.
The model circulatory system reached a limit cycle within 300 cardiac cycles. The
simulation was continued to 500 cardiac cycles. The mean values of pressures,
flows, and volumes were reported only for the last 50 beats. The computer model
was assumed to have no process noise and the deviation in steady-state value
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was less than 1mmHg for pressures, 0.05L/min for flow rates, and 2mL for
ventricular volumes.

Results

Effect of level of support
Increasing levels of CF LVAD support, irrespective of CF LVAD flow modulation,
reduced LVEW, pulse pressures, MAP and SHE and augmented diastolic
coronary flow and myocardial supply demand ratio (CoF/LVEW), from baseline
heart failure values (no LVAD support) (Tables 1-3). CF LVAD flow modulation
increased the range of LVEW, pulse pressures, coronary flows, MAP, SHE and
myocardial supply demand ratios achievable with the same mean CF LVAD flow
rates, Table 2.
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Pulse
Pressure
(mmHg)

Mean
LVAD
Flow
(L/min)

LVEW
(mmHg*mL)

dCoF
(mL/min)

CoF/ LVEW
(mmHg*mL*10-2)-1

Failure

35

0

2854

59

2

Partial Support

15

2.5+0.1

1792

64

3

Full Support

1

5.0+0.1

411

80

14

Asynchronous

Synchronous

Table 1: Pulse pressure, left ventricular external work (LVEW), diastolic
coronary flow (dCoF), and myocardial supply demand ratio (CoF/LVEW)
obtained during baseline heart failure and with partial and full CF LVAD
support without any CF LVAD flow modulation.

Parameter

Pulse Pressure
(mmHg)

LVEW
(mmHg*mL)

dCoF
(mL/min)

CoF/ LVEW
(mmHg*mL*10-2)-1

Full Support

1 - 21

76 - 830

73 - 85

7 - 75

Partial Support

14 - 21

1417 - 2220

61 - 68

2-3

Full Support

2 - 52

317 - 500

77 - 82

11 - 18

Partial Support

18 - 26

1562 - 1873

63 - 66

2-3

Table 2: Range of pulse pressures, left ventricular external work (LVEW),
diastolic coronary flow (dCoF), and myocardial supply demand ratio
(CoF/LVEW) obtained by modulating the CF LVAD flow. These results
demonstrate that modulation and timing of CF LVAD flow resulted in a
range of LVEW and CoF without altering the mean LVAD flow, which may
enable LVAD weaning protocols and myocardial recovery strategies
without altering mean LVAD flow
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Effect of flow modulation amplitude:
Greater LVAD flow modulation amplitudes increased arterial pressure pulsatility
and Surplus Hemodynamic Energy (SHE). Synchronous full support LVAD with
the high flow modulation of 9 L/min (max/min = 10/1 L/min) produced arterial
pulse pressures up to 19 mmHg while low flow modulation produced an arterial
pulse pressure of 1.3 mmHg. For asynchronous full support, a maximum arterial
pulse pressure of 52 mmHg was obtained with an LVAD flow modulation of
9L/min (max/min = 10/1 L/min) at 20 bpm. Both are significantly greater than
pulse pressure of 0.7 mmHg when providing full support with CF LVAD with no
flow modulation.

Increasing LVAD flow modulation augmented the range of LVEW, diastolic CoF,
and the myocardial supply and demand ratio achievable for both full and partial
support (Figure 5). At full LVAD support test condition, LVEW range increased
from 294 – 485 mmHg*mL at low LVAD flow modulation test conditions to 76 –
830 mmHg*mL at high LVAD flow modulation test conditions. During full LVAD
support, the range of diastolic CoF and myocardial supply and demand ratio
increased from 77 - 81 mL/min and 12 - 17(mmHg*mL*10-2)-1 at low LVAD flow
modulation test conditions to 73 - 85 mL/min and 7 - 75 (mmHg*mL*10-2)-1 at high
LVAD flow modulation test conditions. During full LVAD support, different levels
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of flow modulation resulted in a MAP range of 95 - 98 mmHg, EEP range of 96 106 mmHg, and SHE range of 697 – 10863 ergs/cm3.

Figure 5: The effect of amplitude modulation and timing on (a)Surplus
hemodynamic energy (SHE), (b) left ventricular external work (LVEW) and
(c) myocardial supply and demand ratio (CoF/LVEW. Effects of timing are
amplified with increased modulation amplitude. Effects are shown for a
synchronous 60 percent pulse width at low (1L/min), medium (4.5 L/min),
and high (9 L/min) LVAD flow amplitude modulations. These results
indicate that higher amplitude modulation leads to higher SHE, and a larger
variation in LVEW and myocardial supply demand ratio (CoF/LVEW) based
on LVAD flow modulation timing.
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During partial LVAD support, LVEW range increased from 1675 - 1888
mmHg*mL at low LVAD flow modulation test conditions to 1417 - 2220
mmHg*mL at high LVAD flow modulation test conditions. The range of diastolic
CoF and myocardial supply and demand ratio increased from 63 - 65 mL/min and
2.5 - 2.8 (mmHg*mL*10-2)-1 at low LVAD flow modulation test conditions to 61 68 mL/min and 2.1 - 3.4 (mmHg*mL*10-2)-1 at high LVAD flow modulation test
conditions. During partial LVAD support conditions, different levels of flow
modulation resulted in MAP, EEP, and SHE ranges from 78 - 81 mmHg, 80 - 82
mmHg, and 333 - 2144, respectively.

Effect of Timing:
Timing during synchronous LVAD modulation affected LVEW, diastolic CoF, and
CoF/LVEW significantly (Figures 5,6,7). Asynchronous LVAD modulation timing
had negligible effect on any measured parameter, when averaged over several
cardiac cycles (Figure 5). During synchronous full LVAD support with high
pulsatile waveforms, the maximum achievable LVEW, occurred at time shift of
0% and ranged from 407 – 662 mmHg*mL. Minimum achievable LVEW occurred
at time shifts of 40% to 60%, ranged from 76-149 mmHg*mL. Maximum diastolic
CoF (up to 85 mL/min) occurred when the apex of the LVAD flow modulation
waveform occurred during native ventricular diastole (counter pulsation).
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Minimum diastolic CoF occurred when the apex of the LVAD flow modulation
waveform coincided with native ventricular systole (co-pulsation). A change in
time shift from 0% to 40% corresponded with a change in CoF/LVEW ranges of 7
- 8 (mmHg*mL*10-2)-1 to 26 - 75 (mmHg*mL*10-2)-1 at full LVAD support.
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Figure 6: The effects of pulse width and timing on (a) Surplus
hemodynamic energy (SHE), (b) left ventricular external work (LVEW) and
(c) myocardial supply and demand ratio (CoF/LVEW). Counterpulsation
(60% pulse width and 40% time shift) produced minimum LVEW and
maximum CoF/LVEW. Effects are shown for synchronous high (9 L/min)
LVAD flow amplitude modulations at each pulse width (40%, 50%, 60%).
These results indicate that 60% pulse width in co-pulsation mode (0 time
shift) produces the highest pulsatility (SHE) while counter pulsation mode
(40 time shift) produces the highest myocardial supply demand ratio
(CoF/LVEW).
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Figure 7: The effects of LVAD flow modulation rate and timing on (a)
Surplus hemodynamic energy (SHE), (b) left ventricular external work
(LVEW) and (c) myocardial supply and demand ratio (CoF/LVEW). Slower
LVAD flow modulations produced higher SHE. Timing showed little effect
on SHE, LVEW, and CoF/LVEW for asynchronous LVAD flow modulation
(20 BPM. 40 BPM. 60 BPM) as opposed to the effects seen on synchronous
LVAD flow modulation (80 BPM).
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The effects of timing the LVAD flow modulation during partial support test
conditions were similar to full support test conditions. During partial LVAD
support, maximum LVEW ranged from 2057 - 2220 mmHg*mL at 0% time shift.
Minimum LVEW (1417 – 1510 mmHg*mL) were obtained during time shifts of 4060%. Maximum diastolic CoF (67 - 68 mL/min) occurred when the maximum
LVAD flow was during ventricular diastole, while minimum diastolic CoF (61-– 62
mL/min) occurred when maximum LVAD flow was during ventricular systole.
CoF/LVEW ranged from 2.1 - 2.3 (mmHg*mL*10-2)-1 at 0% time shifts to 3.2 3.4 (mmHg*mL*10-2)-1 at 40% time shifts.

Effect of pulse width
Changing the CF LVAD flow modulation pulse width without altering pulse
amplitude affected LVEW, diastolic CoF, and CoF/LVEW (Figure 6). However,
the changes are not as pronounced as the effects of timing.

At full LVAD support test condition with synchronous modulation, the ranges of
LVEW were 149 - 830, 139 - 739, and 76 - 706 mmHg*mL for pulse widths of
40%, 50%, and 60%. Diastolic CoF changed from 73 - 83, 76 - 84, 75 - 85
mL/min at 40%, 50%, and 60% pulse widths. CoF/LVEW at 40%, 50%, and 60%
pulse widths corresponded with ranges of 7 - 38, 8 - 42, and 8 - 75
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(mmHg*mL*10-2)-1. Pulse widths of 20%, 30%, 70%, and 80% required alteration
of the CF LVAD flow modulation amplitude to maintain the average flow rates.
Thus, the effect of timing could not be independently discerned from the effect of
altered CF LVAD flow modulation amplitude for these pulse widths. During
asynchronous modulation at full LVAD support, the ranges of LVEW were 351 500, 355 - 459, and 317 - 420 mmHg*mL for pulse widths of 40%, 50%, and 60%.
Pressure-volume loops are shown in Figure 8.

Figure 8: Pressure volume loops for no LVAD support, CF LVAD support,
pure co-pulsation LVAP flow modulation (0% time shift, 40% pulse width),
pure counter pulsation LVAD flow modulation (40% time shift, 60% pulse
width, LVAD flow modulation with a 50% pulse width starting at systole
(50%PW co-pulsation), and LVAD flow modulation with a 50% pulse with
starting at diastole (50%PW counter-pulsation). Ventricular volumes were
reduced to normal range during LVAD support irrespective of support
condition.
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Diastolic CoF changed from 77 - 80, 78 - 81, and 78 - 82 at 40%, 50%, and 60%
pulse widths. CoF/LVEW at 40%, 50%, and 60% pulse widths corresponded to
ranges of 11 - 16, 13-– 16, and 14 - 18 (mmHg*mL*10-2)-1.

During partial LVAD support with synchronous LVAD flow modulation, LVEW
ranged from 1493 - 2045, 1491- 2117, 1458- 2034, and 1555 - 1944 mmHg*mL
at 20%, 40%, 60%, and 80% pulse widths respectively. The same pulse widths
corresponded with diastolic CoF ranges of 62 - 67, 62 - 67, 62 - 68, and 63 - 66
mL/min, respectively. At 20%, 40%, 60%, and 80% pulse widths, the range of
myocardial supply and demand ratios varied from 2.3 - 3.2, 2.2 - 3.2, 2.3 - 3.3,
and 2.4 - 3.0 (mmHg*mL*10-2)-1.

Asynchronous modulation at partial LVAD support produced LVEW ranges of
1562 - 1873, 1641 - 1856, and 1637 - 1770 mmHg*mL at pulse widths of 40%,
50%, and 60%. Diastolic CoF was 63 - 66 mL/min for all pulse widths. The same
pulse widths corresponded to CoF/LVEW ranges of 2.5 - 3.0, 2.5 - 2.8, and 2.6 2.9 (mmHg*mL*10-2)-1. CF LVAD flow modulation pulse width does not
considerably alter pulse pressure, MAP, EEP, and SHE.
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Synchronous vs. Asynchronous Modulation
During asynchronous LVAD flow modulation, LVEW, diastolic CoF, LVV and
CoF/LVEW varied between cardiac cycles in one LVAD flow modulation
waveform period (Figures 9,10,11) while consistent ranges obtained during
synchronous LVAD support and continuous flow LVAD support. Decreasing the
rate of asynchronous full support LVAD flow modulation increased the achievable
arterial pressure pulsatility, EEP, and SHE. A maximum arterial pulse pressure of
59 mmHg was achieved at a slow LVAD flow modulation rate of 20 bpm (Figure
9). This is significantly greater than synchronous full support CF LVAD with high
flow modulation (19 mmHg at a modulation frequency of 80 bpm). However,
synchronous full and partial support LVAD flow modulations allowed for a larger
range of average LVEW, diastolic CoF, and myocardial supply and demand ratio
ranges compared to asynchronous full and partial support LVAD flow (Tables
2,3).
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Figure 9: AoP, LVP, LVV for Normal CF LVAD, Synchronous CF LVAD with
high flow modulation, and asynchronous CF LVAD with high flow
modulation. Synchronous CF LVAD modulation increases AoP Pulsatility
while maintaining consistent ranges of LVP and LVV. Asynchronous CF
LVAD modulation at 20 BPM increases pulse pressure over synchronous
modulation while creating varying LVP and LVV.
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Figure 10: Values of MAP, EEP and SHE for Asynchronous, Synchronous,
Normal (no CF LVAD flow modulation), and no CF LVAD support. These
results demonstrate that CF LVAD flow modulation does not affect the
mean arterial pressure. However, asynchronous CF LVAD flow modulation
significantly increased SHE.
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Figure 11: Maximum and minimum values of left ventricular volume (LVV)
and aortic pressure (AoP), pulse pressure, mean arterial pressure (MAP),
and ventricular pressure-volume loops showing the varying ventricular
pressures and volumes for different modulation rates of CF LVAD.
Specifically, higher left ventricular volume variability occurs at lower CF
LVAD flow modulation rates.
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Full Support
Partial Support

CF LVAD bpm

MAP (mmHg)

EEP (mmHg)

SHE
(erg/cm3)

20 bpm

95.9 - 98.1

103.6 - 106.1

9,976 - 10,863

40 bpm

95.9 - 98.0

98.5 - 100.8

3,325 - 3,752

60 bpm

96.0 - 97.9

97.2 - 99.3

1,567 -1,850

80 bpm

95.6 - 98.0

96.3 - 98.9

697 - 1,301

20 bpm

79.9 - 80.2

81.3 - 81.6

1,583 - 2.058

40 bpm

79.6 - 80.4

80.5 - 82.0

1,097 - 2,144

60 bpm

79.9 - 80.2

80.8 - 81

1,047 - 1,399

80 bpm

78.6 - 81.3

80.0 - 82.1

333 - 1,899

Table 3: Range of values of mean arterial pressure (MAP), energy
equivalent pressure (EEP), and surplus hemodynamic energy (SHE)
obtained with high modulated CF LVAD flow during full and partial support
at 20, 40, 60, and 80 (synchronous modulation) bpm.

Discussion

The results of this computer simulation study establish that arterial pulsatility and
ventricular work can be affected significantly by modulating CF LVAD flow.
Arterial and ventricular hemodynamic waveforms were altered by varying the
timing, amplitude, and width of the CF LVAD flow modulation pulse for the same
average CF LVAD flow rates. Importantly, a range of LVEW and CoF values can
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be obtained for the same mean CF LVAD flow rate by altering the CF LVAD flow
modulation. Currently, to increase LVEW to wean the patient from the device or
to promote myocardial recovery, the CF LVAD flow rate is lowered, which may
affect end-organ perfusion. Modulation and timing of CF LVAD flow resulted in a
range of LVEW and CoF without altering the mean LVAD flow. Thus, modulation
of CF LVAD flow may be beneficial in developing control strategies for CF LVAD
to obtain a desired myocardial oxygen supply and work level, particularly towards
optimizing the myocardial recovery process and developing weaning protocols
for patients who are likely to experience myocardial recovery without changing
the average CF LVAD flow and affecting end organ perfusion.

Diminished pressure pulsatility due to CF LVAD support has been reported to
diminish aortic wall thickness, and volume ratio of smooth muscle cells [4, 54].
Further, anecdotal reports have indicated the frequent development of adverse
events including gastrointestinal bleeding, hemorrhagic strokes, increased
vascular impedance and progression of aortic valve insufficiency in HF patients
chronically supported by CF LVAD[4, 29-31]. The increase in vascular pulsatility
due to CF LVAD flow modulation may prevent or help reduce the severity of
these adverse events associated with diminished pulsatility.
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Maximum LVEW occurred at 0% time shift (co-pulsation mode) while minimum
LVEW occurred at 40% time shift (counter-pulsation mode). Counterpulsation
mode produced higher myocardial supply demand ratio (CoF/LVEW) but reduced
vascular pulsatility compared to the co-pulsation mode. However, vascular
pulsatility with counter pulsation mode was still higher than what was observed
with no CF LVAD flow modulation. Altering the timing affected the SHE and EEP
values but the highest values of SHE were obtained during asynchronous
support with the LVAD modulating at 20 bpm (Figure 7, Table 3). During
synchronous LVAD flow modulation, co-pulsation mode (0% time shift) resulted
in higher SHE values compared to the counter pulsation mode (40% time shift).
These results suggest that some optimization may be needed to tailor the CF
LVAD flow modulation strategies to individual patients. During asynchronous
LVAD flow modulation at low frequencies and high flow modulations, maximum
pressure pulsatility was achieved. However, High LVAD flow over the period of
several cardiac cycles creates favorable conditions for suction events. Algorithms
to detect and prevent suction have been developed are currently used in
LVADs[55, 56].

A normal human heart produces a peak flow rate of 30-35 L/min and minimum
flow of ~0 L/min, resulting in an aortic pressure pulsatility of approximately 40
mmHg. A failing heart produces a peak flow rate of 20-25 L/min, but still results in
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an aortic pressure pulsatility of 30-35 mmHg due to higher vascular impedance
[4]. We limited the peak flow rate of the simulated CF LVAD flow waveform to 10
L/min to keep within the performance limitations of current LVADs. The minimum
flow rate was limited to 1 L/min to prevent retrograde flow. These limitations in
simulated peak and minimum CF LVAD flows limited the maximum achievable
arterial pressure pulse with synchronous CF LVAD support to 19 mmHg. The
achievable arterial pressure pulse can be significantly increased by allowing
higher values of peak CF LVAD flow rates with improvement in LVAD technology.
While retrograde flows also increase aortic pressure pulsatility, it should be
avoided as it may increase device related hemolysis, LV volumes and LV wall
stresses[57].

Limitations

There are several limitations associated with the computer simulation model. The
performance of the computer simulation during failing heart test condition is
representative of clinical observations from a purely hemodynamic viewpoint.
Clearly, a computer simulation is not intended to replace the importance and
significance of in vivo models and is incapable of replicating all expected clinical
responses, but it does provide a valuable initial step. For instance, the simulation
cannot mimic neurohumoral responses, tissue remodeling, activation of
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regulatory proteins, or changes in genetic phenotype, but it can demonstrate
feasibility of concepts. However, these limitations have been addressed in the invivo animal model studies detailed in chapter 4. Computer models rely upon
many assumptions that may have a dramatic influence upon the interpretation of
results. For example, the computer model for this study assumes ideal valves
that open and close instantaneously, Newtonian blood, a constant diastolic
ventricular compliance, does not account for inertial or gravitational effects, and
the effects of wave reflection. The effect of LVAD flow modulation in mock
circulation and animal experiments, presented in chapters 3 and 4, overcome
some of these limitations. Importantly, blood behaves as a Newtonian fluid at
higher velocities in large vessels and the LVAD. The computer simulation does
enable prediction of hemodynamic and ventricular pressure-volume responses.
The effect of CF LVAD flow modulation can also be quantified in in-vitro mock
circulation systems and in-vivo animal models. However, these models have
several significant limitations not present in the computer simulation that may
affect the accurate quantification of aortic pulse pressure and LVEW. Specifically,
mock circulation models usually lump total systemic compliance which is
significantly lower than aortic compliance[58]. The lower value of lumped
systemic compliance would artificially augment pressure pulsatility, which may
lead to reports of up to 61 mmHg of pressure pulsatility with less than 5 L/min of
flow pulsatility [24]. Similarly, animal models have significantly different aortic and
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arterial compliance values than humans [59]. These altered compliance values
would lead to an inaccurate estimation of aortic pressure pulsatility, Figures 9,
20, and 27. Further, in-vitro mock circulation systems typically underestimate the
reduction in left ventricular peak pressures due to pneumatic/hydraulic drivers,
which may lead to inaccurate estimation of LVEW. Despite its limitations, a
computer simulation model with a simulated aorta may be the simplest method to
adequately quantify the effects of CF LVAD flow modulation. Modulation of CF
LVAD rpm/flow would increase power consumption and bearing wear which may
be minimized in next generation magnetically suspended CF LVAD. To ensure
that the strategies presented in this manuscript are pump independent, we use
flow modulation instead of rpm/power modulation. Pump inertia, friction, and
loading profiles will vary from pump to pump and affect the relationship between
rpm/power modulation and flow modulation. The rpm/power modulation needed
to achieve the flow modulation will be different for each device in mock circulation
and animal studies only being representative of the specific pumps used in each
study. The values of SHE, EEP, pressures, flows, and work are representative
and clinically relevant values obtained from literature but may vary due to intrapatient variability. Despite these limitations, it is hoped that the computer
simulation findings enable the further development and testing of new control
strategies, devices, and experimental protocols that can be translated to an in
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vivo model to validate clinical viability of techniques that promote for myocardial
recovery.
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CHAPTER 3 – MOCK CIRCULATION

Introduction

While they cannot replace in-vivo animal testing and clinical trials, in-vitro mock
loop testing is an important step in the design process. In-vitro mock loops are
used for experimental protocol development, device performance testing,
feedback control algorithm design, as well as training of clinical staff. The in-vitro
test system has the ability to mimic the Frank-Starling response and produces
physiologic characteristic hemodynamic measurements and pressure volumerelationships. The in-vitro mock loop used in this testing has been verified and
well published with multiple devices having been evaluated using it [58, 60-63].
Cases found to yield the most promising results (i.e. co-pulsation and counterpulsation) were further tested using this experimental setup. We hypothesized
that modulation of LVAD RPM will increase arterial pressure pulsatility and
enable alteration of left ventricular pressures, volumes, and workloads. Further,
we hypothesized that the magnitude of these effects on the native ventricle will
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be dependent on LVAD modulation timing. The objective of this mock circulation
study was to investigate the effects of LVAD RPM modulation on the ventricle
and vasculature with varying modulation amplitudes, widths, and frequencies and
compare the results to computer simulation.

Methods and Materials

Mock Circulatory Loop

The mock circulation system used in this experiment consisted of a silicone left
ventricle, aorta, arterial resistance and compliance, venous reservoir and atrial
compliance (Figure 12). Ventricular pressure, heart rate, loop volume,
resistances, and compliances were adjusted to reproduce hemodynamic
pressure and flow waveforms of the physiology of an adult human in heart failure
based on clinical findings. Aortic (proximal and distal) and LVAD flows were
measured using Transonic Flow Probes (Transonic Systems, Ithica, NY). Aortic
(proximal and distal), and atrial pressures were measured using single tipped
Millar pressure catheters and left ventricle pressure and volume were measured
using Millar a pressure-volume conductance catheter (Millar Instruments, TX).
Ventricle systolic and diastolic time periods and pressure, vacuum, and motor
percentages were controlled by the pneumatic ventricle driver (LB Engineering,
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Germany). A HeartWare (Miami Lakes, FL) HVAD was used as the LVAD in this
study. The centrifugal pump has been implanted regularly in Europe, is currently
awaiting FDA approval for bridge to transplantation, and is undergoing clinical
trials for destination therapy in the US [64, 65].

Figure 12: Mock Circulation loop with (a) left ventricle, (b) HeartWare LVAD,
(c) arterial compliance, (d) venous reservoir, and (e) atrial compliance.

LVAD Controller

The LVAD controller was programmed by engineers at HeartWare under the
direction of the investigators to enable LVAD pump speed modulation (Figure
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13). In the mock circulation studies, the controller modulated the LVAD speed up
and down by the same given RPM step around a user defined base speed. The
HVAD has pump has operational speed limits of 1800 – 4000 RPM. Delta T was
defined as the period of time the pump was in high or low RPM (pulse and nadir
rpm). The pump would be in the high RPM for Delta T and the low RPM for Delta
T resulting in one modulation period being twice the value of Delta T. For
example, if a Delta T of 0.4 sec was chosen at a 2900±1100 RPM (mean
RPM±modulation amplitude) modulation, the pump would operate at 4000 RPM
for 0.4 seconds followed by 1800 RPM for 0.4 seconds and then repeat the cycle.
The complete modulation cycle would take 0.8 seconds.

Figure 13: Screenshot of LVAD controller
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Experimental Protocol

Three ventricle contractilities (high, medium, and low) were used in this study.
High contractility produced baseline heart failure pressures in the mock loop with
no LVAD. High, medium, and low contractility resulted in peak ventricle
pressures of 142 mmHg, 104 mmHg, and 80 mmHg. The mock circulation cannot
automatically reduce the contractility based on myocardial load. Thus, different
ventricular contractilities were simulated to match a range of ventricular
contractilities that is observed during unloading/ of the native ventricle
using VAD/LVAD support. The cardiac cycle produced by the driver was 0.795
sec (75.5 BPM), while the LVAD operated at .800 seconds.

Base speeds for this study were chosen at 2900 and 3200 RPM. A base speed
of 2900 allowed for maximum RPM modulation (2900±1100 RPM) (base RPM ±
modulation RPM) and steps of 2900±800 RPM, 2900±500 RPM, and 2900±300
RPM. 3200 RPM completely unloaded the ventricle and was chosen as a full
support baseline with no modulation. Modulations were done around a 3200
RPM base speed at 3200±800 RPM, 3200±500 RPM, and 3200±300 RPM. In
this experiment, periods of 0.4, 0.5, 0.8, and 1.6 were chosen resulting in cycle
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periods of 0.8 seconds, 1.0 seconds, 1.6 seconds, and 3.2 seconds. For
synchronous modulation, the LVAD RPM modulation period was set at 0.4
seconds. The 0.005 second offset between LVAD cycle period (0.8 seconds) and
cardiac cycle (0.795 seconds) allowed for the LVAD to pass from co-pulsation to
counter pulsation LVAD RPM modulation. The small 5 ms difference between the
native ventricle and the pump produced a slightly asynchronous support that
would capture the effect of timing of the LVAD to the native ventricle in a 200
second data set. At each of the three contractilities, the LVAD was modulated at
the described RPM levels at each of the modulation periods. Additionally data
sets were recorded for the LVAD running in CF fashion at each contractility in
100 RPM steps (i.e. 2000 RPM, 2100 RPM, 2200 RPM, etc.

Data Analysis

Data was analyzed using Matlab (MathWorks, Natick, MA) and Hemodynamic
Evaluation and Assessment Research Tool (HEART) program [66]. Pressure,
flow, and volume waveforms were used to calculate the following hemodynamic
parameters: cardiac output; aortic systolic, diastolic, and mean pressures; left
ventricular systolic, end diastolic, and peak pressures; left ventricular external
work; and aortic and LVAD flows. For synchronous LVAD RPM modulation and
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no LVAD RPM modulation, all hemodynamic parameters were calculated on a
beat-to-beat basis. Three beats were averaged for calculating co-pulsation and
counter pulsation hemodynamics; the beat found to be in pure co-pulsation or
counter pulsation and the previous and following beats. When evaluating
synchronous modulation, the hemodynamic values obtained for the modulation
beats were compared to those when operating the LVAD in a CF fashion at flow
within 10% of mean LVAD flow. Asynchronous modulation cases were evaluated
over the full LVAD modulation cycle (i.e. multiple beats) and reported values are
the average of 200 seconds of RPM modulation. Pressure-volume loops were
constructed by plotting ventricular pressure against ventricular volume, where
each loop represents one complete cardiac cycle (one beat). Characterizing
hemodynamic parameters and pressure-volume loops were calculated for all
experimental conditions.

Results

Effects of Contractility

Increased contractility led to greater flow through aortic valve during CF LVAD
support. Table 4 shows flow through the aortic valve proximal to the LVAD
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outflow graft, modulation of LVAD flow rates due to ventricle contraction, and
LVAD speed necessary to achieve mean LVAD flows of 3.0±0.2L/min,
4.0±0.2L/min, and 5.0±0.2L/min at high, medium, and low ventricle contractilities.
Decreasing ventricle contractility resulted in lower LVAD speed necessary for
equivalent LVAD flow. Additionally, increased ventricle contractility resulted in a
higher change in LVAD flow. At LVAD flow rates of 3.0±0.2L/min, 4.0±0.2L/min,
and 5.0±0.2L/min, the change in LVAD flow was 2.6L/min, 2.5L/min, and
2.3L/min for low contractility, 3.6L/min, 3.4L/min, and 3.2L/min for medium
contractility, and 5.4L/min, 4.8L/min, and 4.4L/min for high contractility. Further,
lower ventricle contractility resulted in reduced flow through the aortic valve. At
an LVAD flow rate of 3.0±0.2L/min, flow through the aortic valve diminished from
1.7L/min at high contractility to 0.8L/min at medium contractility and 0.4L/min at
low contractility.

45

VADF
(L/min)

Contractility
Medium
max/min
AoFroot
RPM
VADF
0.8
4.9/1.3
2400

High
max/min
AoFroot
VADF
3.0±0.2
1.7
5.9/0.5

RPM

4.0±0.2

1.0

6.5/1.7

3100

0.2

5.9/2.5

3000

0.0

5.3/2.8

2900

5.0±0.2

0.2

7.3/2.9

3500

0.0

6.6/3.4

3400

0.0

6.1/3.8

3500

2800

Low
max/min
AoFroot
VADF
0.4
4.3/1.7

RPM
2200

Table 4: Flow through the aortic valve proximal to the LVAD outflow graft
(AoFroot), maximum and minimum LVAD flow rates (max/min VADF), and
LVAD speed (RPM) necessary to achieve LVAD flows (VADF) of
3.0±0.2L/min, 4.0±0.2L/min, and 5.0±0.2L/min at high, medium, and low
ventricle contractilities. The LVAD was operating in a CF fashion and the
variation in flow shown in max/min VADF is due to contraction and
relaxation of the ventricle.

During synchronous co-pulsation LVAD RPM modulation, increased ventricular
contractility increased maximum and minimum LVAD flows (Table 5). Change in
LVAD flow increased from 9L/min at low contractility to 9.7L/min and 11.1L/min at
medium and high ventricular contractilities, respectively. In co-pulsation LVAD
RPM modulation, mean LVAD flow increased as ventricle contractility decreased
for maximum LVAD speed modulation (2900±1100 RPM). Differing from copulsation LVAD RPM modulation, in counter pulsation mode, LVAD flow did not
vary greatly between high, medium, and low contractilities with flow rates of
4.1L/min, 4.3L/min, and 4.1 L/min, respectively. Similarly to continuous flow,
decreased contractility resulted in a reduction in flow through the aortic valve for
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both co-pulsation and counter pulsation LVAD RPM modulation. During copulsation LVAD RPM modulation flow through the aortic valve was 1.5L/min,
0.3L/min and 0.0L/min and during counter pulsation LVAD RPM modulation flow
through the aortic valve was 1Lmin, 0.1L/min, and 0.0L/min for high, medium,
and low ventricle contractility, respectively. Low ventricular contractility best
mimics the effects of LVAD unloading the native ventricle and is used in the
remaining of the results section, unless otherwise noted.

Synchronous
LVAD Modulation

Co-pulsation
Counterpulsation

Contractility
High

Medium
Low
AoFroot VADF max/min AoFroot VADF max/min AoFroot VADF max/min
(L/min) (L/min) VADF
(L/min) (L/min) VADF
(L/min) (L/min) VADF
1.5
2.9
8.5/-2.6
0.3
3.5
8.4/-1.3
0.0
3.6
8.2/-0.8
1

4.1

5.4/2.5

0.1

4.3

6.0/2.9

0

4.1

6.4/1.9

Table 5: Flow through the aortic valve proximal to the LVAD outflow graft
(AoFroot), mean LVAD flow (VADF), and maximum and minimum LVAD
flow rates (max/min VADF) at high, medium, and low ventricle
contractilities for co-pulsation and counter pulsation LVAD flow
modulation.

Synchronous vs. Asynchronous Modulation

During asynchronous LVAD RPM modulation, LVEW, LVV, and mean LVAD flow
varied between cardiac cycles occurring during one LVAD RPM modulation cycle
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as compared to consistent ranges obtained during synchronous LVAD support
and continuous flow LVAD support. Decreasing the rate of asynchronous full
support LVAD RPM modulation increased the achievable arterial pressure
pulsatility, EEP, and SHE (Table 6).

Table 6: Range of values of mean arterial pressure (MAP), energy
equivalent pressure (EEP), and surplus hemodynamic energy (SHE)
obtained with maximum modulated CF LVAD RPM around base RPMs of
2900RPM and 3200RPM modulation periods of at 1.6 sec, 0.8 sec, 0.5 sec,
and 0.4 sec (synchronous modulation).
A maximum arterial pulse pressure of 65 mmHg was achieved at a slow LVAD
RPM modulation rate of with a 1.6 second modulation period (3.2 second cycle
period) of 2900±1100RPM. This is considerably greater than synchronous copulsation CF LVAD with a period of 0.4 seconds (20 mmHg at a modulation) and
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synchronous counter pulsation CF LVAD (11 mmHg) with a similar RPM
modulation.

Effects of Timing

Co-pulsation and counter pulsation modulation of LVAD RPM (2900±1100RPM)
both increased pulse pressure 210% and 98%, respectively, as compared to
normal CF LVAD operation with similar mean LVAD flow. However, counter
pulsation yielded more than a 50% smaller percent increase from normal CF
LVAD operation in aortic pressure pulsatility as compared to the greater percent
increase produced by co-pulsation (Figure 14).
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Figure 14: Percent change in pulse pressure during co-pulsation and
counter pulsation LVAD RPM modulation from CF LVAD of similar mean
flow (mean RPM ± modulation RPM).
As compared to co-pulsation, counter pulsation LVAD RPM modulation resulted
in higher mean LVAD flow (3.6L/min vs. 4.1L/min) and MAP (76 mmHg vs. 89
mmHg) at LVAD RPM modulation of 2900±1100 RPM (Figure 15). Co-pulsation
(2900±1100 RPM) increased stroke volume 12% as compared to CF LVAD at
similar flow. Alternatively, counter pulsation (2900±1100 RPM) reduced stroke
volume 20% as compared to CF LVAD at similar flow (Figure 16). Figure 12
shows pressure volume loops for co-pulsation and counter pulsation at
2900±1100 RPM and the corresponding pressure volume loops for CF LVAD
with similar mean LVAD flow, 2700 RPM and 3000 RPM, respectively. Both copulsation and counter pulsation of LVAD RPM at 2900±1100 RPM decreased
LVEW nearly 20% from similar mean CF LVAD flow (Figure 17).
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Figure 15: Aortic pressure, left ventricular pressure, LVAD flow, mean
LVAD flow and pressure volume loops for (a) co-pulsation LVAD
modulation at 2900±1100 RPM, (b) CF LVAD at 2700 RPM, (c) counter
pulsation LVAD RPM modulation at 2900±1100 RPM, and (d) CF LVAD at
3000 RPM. Co-pulsation at 2900±1100 RPM and CF LVAD at 2700 RPM had
similar mean LVAD flows. Further, counter pulsation at 2900±1100 RPM and
CF LVAD at 3000 RPM had similar mean LVAD flows.
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Figure 16: Percent change in stroke volume during co-pulsation and
counter pulsation LVAD RPM modulation from CF LVAD of similar mean
flow (mean RPM ± modulation RPM).

Figure 17: Percent change in LVEW during co-pulsation and counter
pulsation LVAD RPM modulation from CF LVAD of similar mean flow (mean
RPM ± modulation RPM).

52

Effects of Modulation Amplitude

Decrease in RPM modulation amplitude does not considerably change mean
VADF. However, during co-pulsation LVAD RPM modulation a decrease in
modulation amplitude slightly increased mean LVAD flow. Mean LVAD flow
increased from 3.64 L/min to 3.69 L/min, 3.76 L/min, and 3.82 L/min at RPM
modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM,
respectively, during co-pulsation LVAD RPM modulation with a base of 2900
RPM. Alternatively, a decrease in LVAD RPM modulation slightly increased
mean LVAD flow during counter pulsation LVAD RPM modulation. Changes in
RPM modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM
with a base of 2900 RPM resulted in mean LVAD flows of 4.10 L/min, 4.08 L/min,
4.01 L/min, and 3.98 L/min, respectively, for counter pulsation LVAD RPM
modulation (Figure 18).
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Figure 18: Mean LVAD flow for co-pulsation and counter pulsation LVAD
RPM modulation for base RPMs of 2900 RPM and 3000 RPM and for RPM
modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM.

Decrease in RPM modulation amplitude resulted in diminished pulse pressures.
All co-pulsation LVAD RPM modulations resulted in an increase of pulse
pressure as compared to CF LVAD with a similar mean LVAD flow. Similarly,
counter pulsation LVAD RPM modulation resulted in increased pulse pressures
of 98%, 42%, and 36% for LVAD RPM modulations of 2900±1100 RPM,
2900±800 RPM, and 3200±800 RPM. However, counter pulsation LVAD RPM
modulations of 2900±500 RPM, 2900±300 RPM, 3200±500RPM, and 3200±300
RPM resulted in diminished pulse pressures from CF LVAD with a similar mean
LVAD flow of -28%, -61%, -10%, and -56%, respectively (Figure 19). Slower
LVAD RPM modulation resulted in increased pulse pressures (Figure 20). These
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change in pulse pressure trends resulted in similar trends for SHE. All copulsations resulted in increased SHE from CF LVAD with a similar mean LVAD
flow. Furthermore during counter pulsation LVAD RPM modulation, SHE
decreased from CF LVAD with a similar mean LVAD flow of 92% and 92% at a
base of 2900 RPM and 76% and 94% at a base of 3200 RPM, for RPM
modulation amplitudes of 500 RPM and 300 RPM, respectively (Figure 21).

Figure 19: Percent change in pulse pressure during co-pulsation and
counter pulsation LVAD RPM modulation from CF LVAD of similar mean
flow for base RPMs of 2900 and 3200 for RPM modulation amplitudes of
1100 RPM, 800 RPM, 500 RPM, and 300 RPM.
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Figure 20: Aortic pressure (AoP), left ventricular pressure (LVP), and LVAD
flow (VADF) for (a) Normal CF LVAD, (b) Synchronous CF LVAD
(2900±1100RPM) (mean RPM ± modulation RPM), and (c) asynchronous CF
LVAD (2900±1100RPM). Synchronous CF LVAD modulation increases AoP
Pulsatility while maintaining consistent ranges of left ventricular pressure
and volumes. Slow asynchronous CF LVAD modulation at 19 BPM
increases pulse pressure over synchronous modulation while creating
varying left ventricular pressure volumes.
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Figure 21: Percent change in SHE during co-pulsation and counter
pulsation LVAD RPM modulation from CF LVAD of similar mean flow for
base RPMs of 2900 and 3200 for RPM modulation amplitudes of 1100 RPM,
800 RPM, 500 RPM, and 300 RPM.

During co-pulsation LVAD RPM modulation, change in LVAD flow was
diminished as RPM modulation amplitude was decreased from 1100 RPM to 800
RPM, 500 RPM, and 300 RPM. Specifically, for a base of 2900 RPM, change in
LVAD flow decreased from 9.0 L/min at 1100 RPM to 7.2 L/min, 5.2 L/min and
4.1 L/min at 800 RPM, 500 RPM, and 300 RPM, respectively. Similarly for base
RPM of 3200, change in LVAD flow decreased from 7.1 L/min at 800 RPM
modulations to 5.3 L/min at 500 RPM modulations and 4.1 L/min at 300 RPM
modulations (Figure 21). These corresponded to changes in LVAD flow from CF
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LVAD with a similar mean LVAD flow of 242% (±1100 RPM), 176% (±800 RPM),
112% (±500 RPM), and 60%(±300 RPM) at base RPM of 2900 and 201%(±800
RPM), 122%(±500 RPM), and 72%(±300 RPM) at base RPM of 3200 (Figure
22).

During counter pulsation LVAD RPM modulation, change in LVAD flow was
diminished as RPM modulation amplitude was decreased from 1100 RPM to 800
RPM, 500 RPM, and 300 RPM. Specifically, for a base of 2900 RPM, change in
LVAD flow decreased from 4.5 L/min (91%) at 1100 RPM to 3.0 L/min (29%), 1.6
L/min (-36%) and 1.1 L/min (-56%)

at 800 RPM, 500 RPM, and 300 RPM,

respectively. Similarly for base RPM of 3200, change in LVAD flow decreased
from 3.3 L/min (42%) at 800 RPM modulations to 2.0 L/min (-14%) at 500 RPM
modulations and 1.2 L/min (-49%) at 300 RPM modulations where the percent
change from CF LVAD with a similar mean LVAD flow is in parentheses (Figures
22 and 23).
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Figure 22: Change in LVAD flow for co-pulsation and counter pulsation
LVAD RPM modulation for base RPMs of 2900 RPM and 3000 RPM and for
RPM modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM.

Figure 23: Percent change in change in LVAD flow during co-pulsation and
counter pulsation LVAD RPM modulation from CF LVAD of similar mean
flow for base RPMs of 2900 and 3200 for RPM modulation amplitudes of
1100 RPM, 800 RPM, 500 RPM, and 300 RPM.
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The decrease in LVAD RPM amplitude modulation of 2900±1100 RPM, 800 RPM,
and 500 RPM and 3200±800 RPM, 500 RPM, and 300 RPM during co-pulsation
LVAD RPM modulation resulted in attenuation of change in stroke volume from
CF LVAD of similar mean flow. Specifically, change in stroke volumes of 12%,
11%, and 6% and 6%, 10%, and 8% resulted from co-pulsation LVAD RPM
modulations of 2900±1100 RPM, 800 RPM, and 500 RPM and 3200±800 RPM,
500 RPM, and 300 RPM. Counter pulsation LVAD RPM modulation resulted in
change in stroke volumes of -20%, -18%, and -16% and

-14%, -11%, and -7%

for the previously describe cases. Co-pulsation and counter pulsation LVAD RPM
modulation of 2900±300 RPM resulted in increases of 36% and 35% respectively
(Figure 24).
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Figure 24: Percent change in stroke volume during co-pulsation and
counter pulsation LVAD RPM modulation from CF LVAD of similar mean
flow for base RPMs of 2900 and 3200 for RPM modulation amplitudes of
1100 RPM, 800 RPM, 500 RPM, and 300 RPM.

Discussion

The results of this study validate the conclusion that established arterial pulsatility
and ventricular work can be affected significantly by modulating CF LVAD flow
from previous work [44]. Arterial and ventricular hemodynamic waveforms were
altered by varying the timing and amplitude of the CF LVAD RPM modulation and
compared to non-modulation CF LVAD flow with similar mean flows.
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Diminished arterial pulse pressure has been suggested in a mechanism that
results in increased bleeding events, acquired von Willebrande syndrome, and
other adverse events prevalent in the clinical use of CF LVAD [67, 68]. Reduced
pressure pulsatility that occurs during CF LVAD has been reported to diminish
aortic wall thickness and volume ratio of smooth muscle cells [4, 54]. Additionally,
anecdotal reports have indicated the frequent development of adverse events
including gastrointestinal bleeding, hemorrhagic strokes, increased vascular
impedance and progression of aortic valve insufficiency in HF patients chronically
supported by CF LVAD [4, 29-31]. The increase in vascular pulsatility due to CF
LVAD flow modulation may prevent or help reduce the severity of these adverse
events associated with diminished pulsatility. Ando et al previously suggested
that partial support co-pulsation LVAD RPM modulation can increase pulse
pressure near levels of no support in healthy goats [69]. However, this was
achieved with considerable retrograde flow through the device, which resulted in
a 66% increase in end-diastolic LVP suggesting an increase in LVEW.
Furthermore, at low RPM modulation amplitudes, counter pulsation LVAD RPM
modulation would actually provide smaller pulse pressures than non-modulated
CF LVAD flow. This further loss of pressure pulsatility may result in increased
occurrence of adverse events.
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Both co-pulsation and counter pulsation LVAD RPM modulation resulted in a
decreased LVEW as compared to CF LVAD. Further, counter pulsation LVAD
RPM modulation caused a greater decrease in stroke volume than the same copulsation LVAD RPM modulation and as a percent decrease from CF LVAD with
similar mean LVAD flows. Alternately, counter pulsation LVAD RPM modulation
reduced arterial pulse pressure as compared to co-pulsation LVAD RPM
modulation. Counterpulsing by modulating LVAD RPM resulted in smaller
variation in flow as the native ventricular contraction caused a high flow during
systole while high LVAD RPM increased flow during diastole, leading to a smaller
variation in flow during the cardiac cycle compared to copulsation mode.
However, the arterial pulse pressure with counter pulsation LVAD RPM
modulation at high RPM modulation amplitudes (1100 RPM, 800 RPM) was still
higher than observed with no LVAD RPM modulation. Altering the timing of
synchronous LVAD RPM modulation from counter pulsation to co-pulsation mode
resulted in increased pulse pressure, EEP, and SHE. However, asynchronous
modulation produced the highest ranges of MAP, EEP, and SHE, as predicted by
the computer simulation results. Asynchronous LVAD RPM modulation resulted
in beat-to-beat variances in pressures and volumes of the native ventricle. These
variations in beat-to-beat pressures and volumes may be counterproductive for
reversal of heart failure and ultimate recovery of the patient for device
explantation [32].
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It should be noted that retrograde flows also increase aortic pressure pulsatility, it
should be avoided as it may increase device related hemolysis, LV volumes and
LV wall stresses [57, 69]. Retrograde flow was present in this study during
asynchronous LVAD modulation with high RPM modulation of 1100 RPM. This
resulted in prolonged periods of the LVAD operating at its baseline of 1800 RPM.
Additionally, this occurred during co-pulsation LVAD RPM modulation at
2900±1100 RPM.

A normal human heart produces a peak flow rate of 30-35 L/min and minimum
flow of ~0 L/min, resulting in an aortic pressure pulsatility of approximately 40
mmHg. A failing heart produces a peak flow rate of 20-25 L/min, but still results in
an aortic pressure pulsatility of 30-35 mmHg due to higher vascular impedance
[4]. Current LVAD technology is limited in the maximum achievable flows. In this
study, peak LVAD flows of 8.5 L/min occurred during co-pulsation LVAD RPM
modulation at 2900±1100 RPM and asynchronous LVAD RPM at 3200±800RPM
with a period of 1.6 seconds. The current LVAD technology limitations restrict the
maximum achievable pressure pulse, ventricular unloading, and modulation
amplitude. With technological improvements, higher flows and RPM modulation
amplitudes may allow for increased pulse pressure, reduced LVEW, and
prevention of retrograde flow through the LVAD at maximum RPM modulation.
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Limitations

There are several limitations associated with the mock circulation model. For
instance, the mock circulation cannot mimic neurohumoral responses, tissue
remodeling, activation of regulatory proteins, or changes in genetic phenotype,
but it can demonstrate feasibility of concepts and allow for design testing and
improvements without the use of chronic living animal models, which allow for
nuerohumoral responses, tissue remodeling, activation of regulatory proteins,
and changes in genetic phenotype. Furthermore, mock circulation models use
lump total systemic compliance which is significantly lower than aortic
compliance[58]. The lower value of lumped systemic compliance would artificially
augment pressure pulsatility, which may lead to reports of up to 61 mmHg of
pressure pulsatility with less than 5 L/min of flow pulsatility [24]. In our study, we
minimized this effect by having a large compliance

element with low flow

resistance near the aortic root. This enabled a close approximation of physiologic
aortic compliance and approximately 20 mmHg pressure pulsatility with
synchronous LVAD modulation amplitudes of ~9 L/min, as predicted by computer
simulation results. Similarly, animal models have significantly different aortic and
arterial compliance values than humans [59]. These altered compliance values
would lead to an inaccurate estimation of aortic pressure pulsatility, Figures 9,
20, and 27. Further, in-vitro mock circulation systems typically underestimate the
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reduction in left ventricular peak pressures due to pneumatic/hydraulic drivers,
which may lead to inaccurate estimation of LVEW. In this study, three levels of
ventricular contractility were used to mimic the reduced ventricular contractility.
However, in this mock circulation study, fixed ventricular contractility may have
resulted in higher calculated LVEW during counter pulsation LVAD RPM
modulation which resulted in lower stroke volumes than co-pulsation LVAD RPM
modulation but similar peak pressures.

The computer model assumed ideal valves that open and close instantaneously,
Newtonian blood, a constant diastolic ventricular compliance, does not account
for inertial or gravitational effects, and the effects of wave reflection. The mock
circulation model overcame these limitations as it accounted for variable diastolic
ventricular compliance, inertial and gravitational effects, and the effects of wave
reflection. Further, the mock circulation model used mechanical valves which
model realistic valve opening and closing times. However, mechanical valves
resulted in ringing during valve closure, which was filtered out during analysis.
The animal experiments had native valves with realistic opening and closing
without any valve ringing. The mock circulation used a mixture of plasmalyte
solution and water, which is also a Newtonian fluid. However, at these high
velocities, blood acts as a Newtonian fluid. The ventricular contractility in the
mock circulation model is not affected by the degree of ventricular unloading. We
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tried to overcome this limitation by manually reducing the ventricular contractility.
However, a more accurate ventricular volume dependent contractility was
achieved in the computer simulation and animal experiments.

Modulation of CF LVAD RPM would increase power consumption and bearing
wear which may be minimized in using the HeartWare HVAD, a magnetically
suspended CF LVAD. This study only reports the results using the HeartWare
centrifugal HVAD LVAD. Pump inertia, friction, and loading profiles will vary from
pump to pump and affect the relationship between RPM modulation and flow
modulation and the resulting power consumption. The rpm modulation needed to
achieve specific levels of flow modulation will be different for each device which
can be calculated from the pump models.

The mock circulation only represents systemic circulation as it was only intended
to test a LVAD and not a right ventricular assist device or bi-ventricular assist
device. To test flow modulation to these other devices, a pulmonary circulation
must be added. The instrumentation used to record hemodynamics possesses
inherent errors (pressure error = ±1mmHg, flow errors = ±0.5L/min) which the
authors attempted to minimize by using GLP compliant test equipment and
calibration techniques.
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Comparison of Computer Simulation and Mock Circulation Results

Both computer simulation and mock circulation experiments showed similar
results

when

comparing

non-modulation,

asynchronous

modulated

LVAD

flow/RPM

synchronous
(Figures

modulation,
9,

20).

and

However,

Inconsistencies were present during comparisons of computer simulation [44]
and mock circulation results. Specifically, in the computer simulation, copulsation of LVAD flow resulted in increased LVEW while mock circulation results
showed a decrease in LVEW from CF baselines. Additionally, counter pulsation
LVAD flow modulation produced increased pulse pressures in the computer
simulation and decreased pulse pressures in the mock circulation as compared
to non-modulated LVAD flow. It is important to note differences in the study
design of the experiments and specifically the LVAD used in each, which may
have resulted in the described inconsistencies. In the computer simulation the
LVAD was modeled as a flow source in order to allow for back calculation for
various pump specific RPM for individual LVAD to produce simulated flows.
Pump inertia, friction, and loading profiles will vary from pump to pump and affect
the relationship between rpm/power modulation and flow modulation. The
computer simulation was designed to be applicable to any pump that could
produce the constructed flow waveforms under the pressure conditions. However,
this did not allow for simulation of the heart ejecting through the LVAD as
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various pumps would have differing resistances that were not present in the flow
source. Conversely, in the mock loop studies the ventricle ejected through the
pump. This difference may have resulted in the computer simulation showing
increase in LVEW during co-pulsation LVAD flow modulation and the mock loop
study showing a decrease in LVEW during co-pulsation LVAD RPM modulation.

Counterpulsing by modulating LVAD RPM resulted in smaller variation in flow as
the native ventricular contraction caused a high flow during systole while high
LVAD RPM increased flow during diastole, leading to a smaller variation in flow
during the cardiac cycle compared to copulsation mode. This, combined with
ejection through the aortic valve due to higher mock ventricular contractility may
have produced the diminished pulse pressure present during counter pulsation
LVAD RPM/flow modulation in the mock circulation experiments as compared to
the computer simulations. In the mock circulation study, the ventricle ejected
volume while the LVAD was operating in a low speed resulting in a much higher
minimum aortic pressure than seen in the computer simulation. Additionally, invitro mock circulation systems typically underestimate the reduction in left
ventricular peak pressures due to pneumatic/hydraulic drivers, which may lead to
inaccurate estimation of LVEW and in this instance resulted in lower calculated
LVEW in the mock circulation loop as compared to the computer simulation.
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The computer simulation maintained precise control over mean, peak, and
minimum LVAD flows. Conversely, the HVAD used in the mock loop studies
could only control RPM and not specific flows. In mock circulation studies, copulsation and counter pulsation LVAD RPM modulation resulted in differing mean
LVAD flow rates. In this case the two modulation timings could not be directly
compared as they were in the computer simulation and may have resulted in
varying degrees of change from non-modulated LVAD flow/rpm baselines.
Furthermore, the computer simulation allowed for multiple pulse widths which
enabled pure co-pulsation and counter pulsation LVAD flow modulation. The
HVAD controller could only produce a 50% pulse width due to programming
limitations and thus was not in “pure” co-pulsation or counter pulsation. Figure 8
shows in computer simulations that synchronization with a 50% pulse width
would yield decreased LVEW as compared to 40% pulse width during copulsation and increased LVEW compared to 60% pulse width during counter
pulsation. Additionally, since the HVAD controller could not be triggered off of an
ECG or pressure waveform, the controller was phased in and out of co-pulsation
and counter pulsation modes by offsetting the LVAD cycle time (0.8 seconds)
and the beat time (0.795 seconds) by 0.005 seconds. Future iterations of the
HVAD controller will include ECG triggering and pulse width features.
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CHAPTER 4 – Pilot in-vivo ANIMAL STUDY

Introduction

Computer simulation and mock circulatory model testing are important steps in
the development of LVAD control strategies. However, they cannot replace invivo animal testing and clinical trials as they cannot mimic neurohumoral
responses, tissue remodeling, activation of regulatory proteins, or changes in
genetic phenotype. Animal model testing is an important step in proving device
and control strategy safety for the ultimate advancement to clinical therapy.
However, normal animal models do not adequately simulate a human in heart
failure to allow for efficacy testing. Thus, we present preliminary findings of LVAD
RPM modulation in an ischemic bovine heart failure model and normal calf. We
hypothesize that modulation of LVAD RPM will increase arterial pressure
pulsatility and alter left ventricular pressures, volumes, and workloads. Further,
the effect on the ventricle will be dependent on timing. We hypothesized that
modulation of LVAD RPM will increase arterial pressure pulsatility and enable
alteration of left ventricular pressures, volumes, and workloads. Further, we
hypothesized that the magnitude of these effects on the native ventricle will be
dependent on LVAD modulation timing. The objective of this pilot animal study
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was to investigate the effects of LVAD RPM modulation on the ventricle and
vasculature with varying modulation amplitudes, widths, and frequencies and
compare the results to computer simulation and mock circulation results.

Methods and Materials

Animals

Male, mixed-breed calves (n=2) were used in this study. Heart failure was
induced in the two animals using micro-embolization techniques and implanted
with HeartWare LVAD 60-days later for LVAD RPM modulation testing while
under anesthesia. The HeartWare HVAD centrifugal LVAD was used in this study.
All animals received humane care and were handled in accordance with National
Institutes of Health and the University of Louisville animal care committee
guidelines. All experimental procedures were approved by the University of
Louisville Institutional Animal Care and Usage Committee.

LVAD Controller

The LVAD controller was programmed to modulate LVAD RPM by engineers at
HeartWare under the direction of the investigators (Figure 25). For the in-vivo
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animal studies, the controller modulated the LVAD speed up and down by user
given RPM steps around a user defined base speed. The HeartWare HVAD has
pump defined speed limits of 1800 – 4000 RPM. The controller allowed for
modulation periods with a minimum of 0.20 seconds in 0.01 second increases.
The pump would be in high RPM (base RPM plus high RPM modulation
amplitude) for the high RPM period and the low RPM (base RPM minus low RPM
modulation amplitude) for the low RPM period. For example, if a high RPM
period of 0.35 sec was chosen with an 1100 RPM modulation amplitude, a low
RPM period of 0.4 sec with an 800 RPM modulation amplitude, and a base RPM
of 2900, the pump would operate at 2100 RPM for 0.4 seconds followed by 4000
RPM for 0.35 seconds and then repeat the cycle. The complete modulation cycle
would take 0.75 seconds. The controller also allowed for ECG-triggered
modulation. Once the ECG signal went above a user defined threshold, the
LVAD would operate through the modulation cycle and then wait for the next
instance where the ECG threshold was exceeded before operating through the
modulation cycle again.
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Figure 25: Screenshot of LVAD controller

Terminal Study

Sixty-days after micro-embolization (n=2) a terminal study was performed to
measure the acute hemodynamic effects of LVAD RPM modulation. Anesthesia
was induced and maintained in the proper fashion. The animal was placed on
the operating table in right lateral recumbency. Fluid-filled arterial and venous
catheters were placed in the left carotid artery and jugular vein for blood
sampling.

A left thoracotomy was performed.

Ribs #4 and #5 were

resected. The pericardium was opened and the LVAD implanted.
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At the start of the LVAD RPM modulation experiment, a single-tip, high-fidelity
micromanometer catheter (Millar Instruments, Houston,TX) was placed in the
aorta and a dual pressure-volume conductance catheter (Millar Instruments,
Houston, TX) was advanced from the left atrium across the mitral valve into the
left ventricle for simultaneous measurement of aortic, left atrial, and left
ventricular blood pressures. A transit-time ultrasonic flow probe (Transonics,
Ithaca, NY) was placed around the pulmonary artery to measure cardiac output.

Data Reduction

All transducers were pre- and post-calibrated against known physical standards
to ensure measurement accuracy. Calibration curves for the volume conductance
catheter were constructed using static and dynamic tests pre- and postexperiment. Hemodynamic data were collected at 400Hz, signal conditioned,
and A/D converted for digital analysis using our GLP compliant data acquisition
system.

To determine the acute effects of LVAD RPM modulation, pressure and flow
waveforms were used to derive heart rate, left ventricular end-diastolic pressure,
left ventricular peak-systolic pressure, ±dP/dt, mean aortic pressure, systolic
aortic pressure, diastolic aortic pressure, aortic pulse pressure, HR x LVPpeak
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systolic, a standard index of cardiac metabolic demand, pulmonary artery flow as
an index of cardiac output, and CO normalized to animal weight. Hemodynamic
indices were calculated on a beat-to-beat basis for each 30 second data set with
the Hemodynamic Evaluation and Assessment Research Tool (HEART) program
developed in Matlab (Version 6.5, MathWorks, Natick, MA). All analyzed beats in
each data set (approximately 30 to 50beats/30 second data set) were averaged
to obtain a single representative mean value for each calculated variable.

Preliminary Results
LVAD RPM modulation was tested in two animals. In one animal, no data sets of
non-modulated flow were taken for comparison. In one animal non-modulated
LVAD RPM (2900RPM) and counter pulsation LVAD RPM modulation were
compared (2900±1100RPM) (mean RPM ± modulation RPM).

Mean and

diastolic coronary flows were increased 24% and 80%, respectively, during
counter pulsation LVAD RPM modulation. However, systolic coronary flow was
decreased by 30%. Aortic pulse pressure was increase from 2 mmHg at CF
LVAD to 15 mmHg at counter pulsation LVAD RPM modulation. However, in
these two cases, heart rate, mean LAVD flow, and cardiac output were 20%
greater during LVAD RPM modulation than during non-modulated CF LVAD
(Table 7).

Additionally, ventricular volume was decreased during counter
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pulsation LVAD RPM modulation as compared to non-modulated LVAD RPM
(Figure 26).

During asynchronous LVAD RPM modulation, pressures and

volumes varied on a beat to beat basis and pulse pressure of up to 10 mmHg
were achieved (Figure 27).

Condition
CF VAD 2900 RPM
Counter pulse 2900 + 1100

HR
70
85

SV
66
65

CO
4.6
5.5

VADF
4.4
5.3

% change

20

-1

19

20

LVPed LVPpks
8
34
9
53
13

54

MAP
44
41
-6

AoPpulse CAFmean CAFavgsys CAFavdias
2
163
143
163
15
202
100
294
793

24

-30
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Table 7: Heart rate (HR), stroke volume (SV), cardiac output (CO), mean
LVAD flow (VADF), left ventricular end diastolic pressure (LVPed), peak
systolic left ventricular pressure (LVPpks), mean aortic pressure (MAP),
aortic pulse pressure (AoPpulse), mean coronary flow (CAFmean), mean
systolic coronary flow (CAFavsys), and mean diastolic coronary flow
(CAFavdias) for CF LVAD and counter pulsation LVAD RPM modulation
with same mean VADF.
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Figure 26: Aortic pressure, left ventricular pressure, LVAD flow, coronary
artery flow (CAF), ECG, and pressure volume loops for counter pulsation
LVAD RPM modulation (2900±1100RPM) (mean RPM ± modulation RPM)
and non-modulated LVAD RPM (2900RPM).
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Figure 27: Aortic pressure, left ventricular pressure, left ventricular volume
for Normal CF LVAD, Synchronous CF LVAD (3200±800RPM), and
asynchronous CF LVAD (3200±800RPM) (mean RPM ± modulation RPM).
Synchronous CF LVAD modulation increases AoP Pulsatility while
maintaining consistent ranges of left ventricular pressure and volumes.
Asynchronous CF LVAD modulation at 19 BPM increases pulse pressure
over synchronous modulation while creating varying left ventricular
pressure volumes.
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Discussion
The pilot animal study produced similar results as the computer simulation and
mock circulation studies in proving that LVAD RPM modulation can reduce left
ventricular volumes and increase arterial pulse pressure. Additionally, animals
studied showed increased pressure pulsatility with slow asynchronous LVAD
RPM modulation.

Unfortunately, the hemodynamic state of the animal cannot be held constant
through all measurement sets due to changes in medications, deterioration of the
surgical preparation, loss of blood volume, and other factors. Further, full
unloading was not always achieved with the calf model as the calf has a
significantly higher cardiac output compared to humans. Thus, in Figure 26
synchronous LVAD RPM modulation is only providing partial support, and thus
results in a higher pulse pressure than non-modulated LVAD flow, which is fully
unloading the ventricle. Additionally, Figure 27 (a) CF LVAD 3200RPM and (c)
Asynchronous LVAD 3200±800RPM are from a different animal than (b)
Synchronous LVAD 3200±800RPM. These data sets were chosen as they were
the only three cases of full support showing their respective LVAD RPM
modulation. The initial pilot study is severely limited in its ability to show
comparative results and draw definitive conclusions. However, we have shown
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that preliminary findings in an in-vivo animal model produce similar results to
those seen in computer simulations and mock circulation models.

Limitations
Animal models are not as stable of a testing platform as the computer simulation
and mock circulation studies due to deterioration of the surgical preparation,
effects of drugs, and variabilities in heart rates, ventricular contractilities and
resistances due to physiologic and neurohormonal responses and other
mechanisms. This results in increased variation between data sets and a
diminished ability to directly compare data sets, which was minimized by
collection of several intermediate baselines to facilitate comparisons. The acute
animal model incorporates neurohumoral responses, and activation of regulatory
proteins which are absent in the computer simulation and mock circulation
studies. Animal models have significantly different aortic and arterial compliance
values than humans [59]. Specifically, the calf model has a significantly higher
compliance compared to humans. These altered compliance values would lead
to a lower and inaccurate estimation of aortic pulse pressure due to LVAD
modulation compared to computer simulation and mock circulation experiments,
Figures 9, 20, and 27.
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Modulation of CF LVAD RPM increased power consumption and potentially
increases bearing wear which may be minimized in using the HeartWare HVAD,
a magnetically suspended CF LVAD. This study only reports the results using the
HeartWare centrifugal HVAD LVAD. Pump inertia, friction, and loading profiles
will vary from pump to pump and affect the relationship between RPM modulation
and flow modulation and the resulting power consumption. However the
principles of RPM/flow modulation and increasing vasculature pulsatility is pump
independent as evinced by the computer simulation study. The instrumentation
used to record hemodynamics possesses inherent errors (pressure error =
±1mmHg, flow errors = ±0.5L/min) which the authors attempted to minimize by
using GLP compliant test equipment and calibration techniques.
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Conclusions

The results of this study establish that arterial pulsatility and ventricular work can
be affected significantly by modulating CF LVAD flow. Arterial and ventricular
hemodynamic waveforms were altered by varying the timing, amplitude, and
width of the LVAD flow modulation pulse for the same average LVAD flow rates.
Importantly, a range of LVEW and CoF values can be obtained for the same
mean CF LVAD flow rate by altering the LVAD flow modulation without
significantly affecting end-organ perfusion. Thus, these LVAD flow/RPM
modulations may reduce the incidence of adverse events associated with the CF
LVAD therapy by increasing vascular pulsatility and reducing vascular
impedance. Further, these methods of LVAD flow/RPM modulation may enable
tailored unloading of the native ventricle to provide rest and rehabilitation
(maximal unloading to rest followed by gradual reloading to wean), which may
promote sustainable myocardial recovery.
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